Opdivo’s EU Colorectal Cancer Setback ‘More Than Offset’ By Potential Gains In Combination

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Digital illustration of Cancer cell in colour background
BMS has withdrawn its EU Opdivo filing for colorectal cancer

Bristol-Myers Squibb Co.’s decision to pull its EU application to use its PD-1 inhibitor Opdivo (nivolumab) in the additional indication of metastatic colorectal cancer (mCRC) follows a similar withdrawal for the drug in liver cancer last year.

This is something of a regulatory setback for BMS, but in commercial terms the latest withdrawal is unlikely to have...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip